# EDGAR Filing Document

**Accession Number:** 0001940272
**File Stem:** 0001940272-25-000006
**Filing Date:** 2025-8
**Character Count:** 73940
**Document Hash:** 829bf72c596c29e0f97ec1cf96a5298f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001940272-25-000006.hdr.sgml**: 20250827

**ACCESSION NUMBER**: 0001940272-25-000006

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250827

**EFFECTIVENESS DATE**: 20250827

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ADAR1 Capital Management, LLC
- **CENTRAL INDEX KEY:** 0001940272

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-23931
- **FILM NUMBER:** 251263211

**BUSINESS ADDRESS:**
- **STREET 1:** 3503 WILD CHERRY DRIVE
- **STREET 2:** BUILDING 9
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78738
- **BUSINESS PHONE:** 512-254-3790

**MAIL ADDRESS:**
- **STREET 1:** 3503 WILD CHERRY DRIVE
- **STREET 2:** BUILDING 9
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78738

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001940272

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** ADAR1 Capital Management, LLC

**Address:** 3503 WILD CHERRY DRIVE, AUSTIN, TX 78738

**Telephone number:** 512-254-3790

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-23931

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** 549300YNEBMYE1SWQH64

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                             | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                                                                                                       | VOTE CATEGORY                |     SHARES VOTED |   SHARES ON LOAN | HOW VOTED   | SHARES VOTED FOR OR AGAINST MANAGEMENT   | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|:---|:---|:---|
| Mitek Systems, Inc.                        | 606710200 | 03/04/2025     | To approve, on an advisory (non-binding) basis, the compensation of our named executive officers as presented in the Proxy Statement accompanying this notice.                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |     39           |                0 | FOR         | 39.000000                                | FOR                         |  |
| Arrowhead Pharmaceuticals, Inc.            | 04280A100 | 03/12/2025     | Advisory Vote to Approve Executive Compensation.                                                                                                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |  18372           |                0 | FOR         | 18372.000000                             | FOR                         |  |
| Arrowhead Pharmaceuticals, Inc.            | 04280A100 | 03/12/2025     | Advisory Vote on Frequency of Executive Compensation Advisory Votes.                                                                                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |  18372           |                0 | ONE YEAR    | 18372.000000                             | FOR                         |  |
| Intra-Cellular Therapies, Inc.             | 46116X101 | 03/27/2025     | To approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to ITI's named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement.                         | SECTION 14A SAY-ON-PAY VOTES |  22673           |                0 | AGAINST     | 22673.000000                             | AGAINST                     |  |
| Pfizer Inc.                                | 717081103 | 04/24/2025     | 2025 advisory approval of executive compensation                                                                                                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |  50050           |                0 | AGAINST     | 50050.000000                             | AGAINST                     |  |
| Verona Pharma Plc                          | 925050106 | 04/24/2025     | To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.                                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |  19212           |                0 | AGAINST     | 19212.000000                             | AGAINST                     |  |
| Moderna, Inc.                              | 60770K107 | 04/30/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers.                                                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |   7820           |                0 | AGAINST     | 7820.000000                              | AGAINST                     |  |
| Biohaven Ltd.                              | G1110E107 | 05/05/2025     | A non-binding advisory vote on the compensation of the Company's named executive officers.                                                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |  19855           |                0 | FOR         | 19855.000000                             | FOR                         |  |
| Mereo BioPharma Group Plc                  | 589492107 | 05/13/2025     | That the compensation of the Company's named executive officers be approved, on an advisory (non-binding) basis.                                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |   9800           |                0 | FOR         | 9800.000000                              | FOR                         |  |
| Mereo BioPharma Group Plc                  | 589492107 | 05/13/2025     | That the frequency of future advisory votes on the compensation of the Company's named executive officers be approved, on an advisory (non-binding) basis.                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |   9800           |                0 | ONE YEAR    | 9800.000000                              | AGAINST                     |  |
| Cytokinetics, Incorporated                 | 23282W605 | 05/14/2025     | To approve, on an advisory basis, the compensation of Cytokinetics, Incorporated's named executive officers, as disclosed in the Proxy Statement.                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES | 307674           |                0 | FOR         | 307674.000000                            | FOR                         |  |
| Ichor Holdings, Ltd.                       | G4740B105 | 05/14/2025     | Advisory approval of the compensation of our named executive officers.                                                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |    108           |                0 | FOR         | 108.000000                               | FOR                         |  |
| SpringWorks Therapeutics, Inc.             | 85205L107 | 05/14/2025     | Non-binding advisory vote on executive compensation                                                                                                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES | 166258           |                0 | FOR         | 166258.000000                            | FOR                         |  |
| Delcath Systems, Inc.                      | 24661P807 | 05/15/2025     | To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement ("Proxy Statement").                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES | 149385           |                0 | FOR         | 149385.000000                            | FOR                         |  |
| Insmed Incorporated                        | 457669307 | 05/15/2025     | An advisory vote on the 2024 compensation of our named executive officers.                                                                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |   5099           |                0 | FOR         | 5099.000000                              | FOR                         |  |
| Nordstrom, Inc.                            | 655664100 | 05/16/2025     | To approve, on a non-binding, advisory basis, certain compensation that will or may become payable by Nordstrom to its named executive officers in connection with the merger of Navy Acquisition Co. Inc., a wholly owned subsidiary of Norse Holdings, Inc. with and into Nordstrom. | SECTION 14A SAY-ON-PAY VOTES |  11634           |                0 | FOR         | 11634.000000                             | FOR                         |  |
| Viking Therapeutics, Inc.                  | 92686J106 | 05/20/2025     | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.                                                                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |  35359           |                0 | AGAINST     | 35359.000000                             | AGAINST                     |  |
| Arbutus Biopharma Corporation              | 03879J100 | 05/21/2025     | To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement/Circular; and                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES | 454920           |                0 | FOR         | 454920.000000                            | FOR                         |  |
| Geron Corporation                          | 374163103 | 05/21/2025     | To approve, on an advisory basis, the compensation of our Named Executive Officers, as disclosed in our Proxy Statement.                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES | 105852           |                0 | FOR         | 105852.000000                            | FOR                         |  |
| NCR Atleos Corporation                     | 63001N106 | 05/21/2025     | Consider and vote to approve, on a non-binding and advisory basis, the compensation of the named executive officers ("Say on Pay"), as more particularly described in these proxy materials.                                                                                           | SECTION 14A SAY-ON-PAY VOTES |   1000           |                0 | FOR         | 1000.000000                              | FOR                         |  |
| Capricor Therapeutics, Inc.                | 14070B309 | 05/22/2025     | APPROVAL OF NAMED EXECUTIVE OFFICER COMPENSATION, ON A NON-BINDING ADVISORY BASIS                                                                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |    120           |                0 | FOR         | 120.000000                               | FOR                         |  |
| Dianthus Therapeutics, Inc.                | 252828108 | 05/22/2025     | To approve, on an advisory basis, the compensation paid to our named executive officers; and                                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |  12141           |                0 | AGAINST     | 12141.000000                             | AGAINST                     |  |
| SCHOLAR ROCK HOLDING CORPORATION           | 80706P103 | 05/22/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES | 105511           |                0 | FOR         | 105511.000000                            | FOR                         |  |
| 89bio, Inc.                                | 282559103 | 05/28/2025     | Approval of, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES | 798138           |                0 | FOR         | 798138.000000                            | FOR                         |  |
| Arcellx, Inc.                              | 03940C100 | 05/28/2025     | To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the "Executive Compensation" section of the proxy statement.                                                                                   | SECTION 14A SAY-ON-PAY VOTES |   5004           |                0 | FOR         | 5004.000000                              | FOR                         |  |
| Checkpoint Therapeutics, Inc.              | 162828206 | 05/28/2025     | To consider and vote on the proposal to approve, on a non-binding, advisory basis, the compensation that will or may become payable by Checkpoint to its named executive officers in connection with the Merger (the "Compensation Proposal").                                         | SECTION 14A SAY-ON-PAY VOTES | 251654           |                0 | FOR         | 251654.000000                            | FOR                         |  |
| Acadia Pharmaceuticals Inc.                | 004225108 | 05/29/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |   1615           |                0 | FOR         | 1615.000000                              | FOR                         |  |
| Perimeter Solutions, Inc.                  | 71385M107 | 05/29/2025     | To approve, on an advisory basis, the compensation of our named executive officers ("Say on Pay").                                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |   9000           |                0 | FOR         | 9000.000000                              | FOR                         |  |
| Rapt Therapeutics, Inc.                    | 75382E208 | 05/29/2025     | To approve, on an advisory basis, the compensation of RAPT Therapeutics, Inc.'s name executive officers.                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |      5.02694e+06 |                0 | AGAINST     | 5026936.000000                           | AGAINST                     |  |
| Rapt Therapeutics, Inc.                    | 75382E208 | 05/29/2025     | To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of RAPT Therapeutics, Inc.'s named executive officers.                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |      5.02694e+06 |                0 | ONE YEAR    | 5026936.000000                           | FOR                         |  |
| Spyre Therapeutics, Inc.                   | 00773J202 | 05/29/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |  14605           |                0 | FOR         | 14605.000000                             | FOR                         |  |
| Vir Biotechnology, Inc.                    | 92764N102 | 05/29/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES | 222082           |                0 | FOR         | 222082.000000                            | FOR                         |  |
| REGENXBIO Inc.                             | 75901B107 | 05/30/2025     | Advisory vote on the compensation paid to the Company's named executive officers.                                                                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES | 179937           |                0 | FOR         | 179937.000000                            | FOR                         |  |
| REGENXBIO Inc.                             | 75901B107 | 05/30/2025     | Advisory vote on the frequency of future stockholder advisory votes on the compensation paid to the Company's named executive officers.                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES | 179937           |                0 | ONE YEAR    | 179937.000000                            | FOR                         |  |
| Day One Biopharmaceuticals, Inc.           | 23954D109 | 06/02/2025     | Approval, on a non-binding advisory basis, of the compensation of our named executive officers.                                                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |  18019           |                0 | FOR         | 18019.000000                             | FOR                         |  |
| Oruka Therapeutics, Inc.                   | 687604108 | 06/02/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers.                                                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |  73959           |                0 | FOR         | 73959.000000                             | FOR                         |  |
| Oruka Therapeutics, Inc.                   | 687604108 | 06/02/2025     | To vote, on a non-binding, advisory basis, on the frequency of future advisory votes to approve compensation for our named executive officers.                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |  73959           |                0 | ONE YEAR    | 73959.000000                             | FOR                         |  |
| Akero Therapeutics, Inc.                   | 00973Y108 | 06/03/2025     | To consider and act upon a non-binding, advisory vote to approve the compensation of our named executive officers.                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |  39928           |                0 | FOR         | 39928.000000                             | FOR                         |  |
| Apellis Pharmaceuticals, Inc.              | 03753U106 | 06/03/2025     | To hold an advisory vote to approve the compensation paid to our named executive officers;                                                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |  17000           |                0 | FOR         | 17000.000000                             | FOR                         |  |
| Apellis Pharmaceuticals, Inc.              | 03753U106 | 06/03/2025     | To hold an advisory vote on the frequency of future advisory votes on the compensation paid to our named executive officers; and                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |  17000           |                0 | ONE YEAR    | 17000.000000                             | FOR                         |  |
| Denali Therapeutics Inc.                   | 24823R105 | 06/03/2025     | Advisory vote on executive compensation                                                                                                                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |   4124           |                0 | FOR         | 4124.000000                              | FOR                         |  |
| Kiniksa Pharmaceuticals International, plc | G52694109 | 06/03/2025     | To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.                                                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |  32154           |                0 | FOR         | 32154.000000                             | FOR                         |  |
| Phathom Pharmaceuticals, Inc.              | 71722W107 | 06/03/2025     | To approve the compensation of the named executive officers on a non-binding advisory basis ("say-on-pay").                                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |  10000           |                0 | FOR         | 10000.000000                             | FOR                         |  |
| Phathom Pharmaceuticals, Inc.              | 71722W107 | 06/03/2025     | To approve a proposal for the frequency of future non-binding advisory votes on the compensation of the named executive officers ("say-on-frequency").                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |  10000           |                0 | ONE YEAR    | 10000.000000                             | FOR                         |  |
| Voyager Therapeutics, Inc.                 | 92915B106 | 06/03/2025     | To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |  26854           |                0 | FOR         | 26854.000000                             | FOR                         |  |
| Keros Therapeutics, Inc.                   | 492327101 | 06/04/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the accompanying Proxy Statement.                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |      2.51282e+06 |                0 | AGAINST     | 2512823.000000                           | AGAINST                     |  |
| Kiora Pharmaceuticals, Inc.                | 49721T507 | 06/04/2025     | To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement.                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES | 183041           |                0 | FOR         | 183041.000000                            | FOR                         |  |
| NewAmsterdam Pharma Company N.V.           | N62509109 | 06/04/2025     | Non-binding, advisory vote to approve the 2024 compensation of named executive officers.                                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |  83359           |                0 | FOR         | 83359.000000                             | FOR                         |  |
| NewAmsterdam Pharma Company N.V.           | N62509109 | 06/04/2025     | Non-binding, advisory vote regarding frequency of future shareholders' advisory votes on the compensation of named executive officers.                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |  83359           |                0 | ONE YEAR    | 83359.000000                             | FOR                         |  |
| Ventyx Biosciences, Inc.                   | 92332V107 | 06/04/2025     | To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the "Executive Compensation" section of the proxy statement (the "Say-on-Pay Vote").                                                           | SECTION 14A SAY-ON-PAY VOTES | 281600           |                0 | AGAINST     | 281600.000000                            | AGAINST                     |  |
| Xenon Pharmaceuticals Inc.                 | 98420N105 | 06/04/2025     | To approve, on an advisory basis, the compensation of the Corporation's named executive officers;                                                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES | 178950           |                0 | FOR         | 178950.000000                            | FOR                         |  |
| Amylyx Pharmaceuticals, Inc.               | 03237H101 | 06/05/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executives officers.                                                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |      1.44529e+06 |                0 | AGAINST     | 1445287.000000                           | AGAINST                     |  |
| Celldex Therapeutics, Inc.                 | 15117B202 | 06/05/2025     | To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in this Proxy Statement.                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |   1897           |                0 | FOR         | 1897.000000                              | FOR                         |  |
| MoonLake Immunotherapeutics                | 61559X104 | 06/05/2025     | Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |   1127           |                0 | FOR         | 1127.000000                              | FOR                         |  |
| Pliant Therapeutics, Inc.                  | 729139105 | 06/05/2025     | To approve, by non-binding advisory vote, the resolution approving Named Executive Officer compensation.                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |    851           |                0 | AGAINST     | 851.000000                               | AGAINST                     |  |
| Sarepta Therapeutics, Inc.                 | 803607100 | 06/05/2025     | ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION                                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES | 110796           |                0 | FOR         | 110796.000000                            | FOR                         |  |
| Savara Inc.                                | 805111101 | 06/05/2025     | To approve, on an advisory basis, the compensation of our named executives.                                                                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |      1.33582e+06 |                0 | FOR         | 1335816.000000                           | FOR                         |  |
| Savara Inc.                                | 805111101 | 06/05/2025     | To indicate, on an advisory basis, the preferred frequency of holding an advisory vote on the compensation of our named executives.                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |      1.33582e+06 |                0 | ONE YEAR    | 1335816.000000                           | FOR                         |  |
| Teva Pharmaceutical Industries Limited     | 881624209 | 06/05/2025     | TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION FOR TEVA'S NAMED EXECUTIVE OFFICERS                                                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES | 437172           |                0 | FOR         | 437172.000000                            | FOR                         |  |
| Abivax SA                                  | 00370M103 | 06/06/2025     | Approve Compensation of Marc de Garidel, Acting Chairman of the Board and CEO                                                                                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |      2.12096e+06 |                0 | AGAINST     | 2120959.000000                           | AGAINST                     |  |
| Abivax SA                                  | 00370M103 | 06/06/2025     | Approve Compensation of Sylvie Gregoire, Chairwoman of the Board                                                                                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |      2.12096e+06 |                0 | AGAINST     | 2120959.000000                           | AGAINST                     |  |
| Marker Therapeutics, Inc.                  | 57055L206 | 06/06/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |   2432           |                0 | FOR         | 2432.000000                              | FOR                         |  |
| Surgery Partners, Inc.                     | 86881A100 | 06/06/2025     | Approval, on an advisory basis, of the compensation paid by the Company to its named executive officers.                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |   6921           |                0 | AGAINST     | 6921.000000                              | AGAINST                     |  |
| Tectonic Therapeutic, Inc.                 | 878972108 | 06/06/2025     | Advisory approval of the compensation of the Company's Named Executive Officers.                                                                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |  61857           |                0 | FOR         | 61857.000000                             | FOR                         |  |
| Tectonic Therapeutic, Inc.                 | 878972108 | 06/06/2025     | Advisory vote on the frequency of stockholder advisory votes on executive compensation.                                                                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |  61857           |                0 | ONE YEAR    | 61857.000000                             | FOR                         |  |
| Aldeyra Therapeutics, Inc.                 | 01438T106 | 06/10/2025     | To approve, on a non-binding, advisory basis, the compensation of Aldeyra Therapeutics, Inc.'s named executive officers.                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES | 510888           |                0 | FOR         | 510888.000000                            | FOR                         |  |
| Clover Health Investments, Corp.           | 18914F103 | 06/10/2025     | Non-binding advisory proposal to approve the compensation paid to our named executive officers for 2024.                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |  48300           |                0 | FOR         | 48300.000000                             | FOR                         |  |
| Iovance Biotherapeutics, Inc.              | 462260100 | 06/10/2025     | To approve, by non-binding advisory vote, the compensation of our named executive officers;                                                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |  15000           |                0 | FOR         | 15000.000000                             | FOR                         |  |
| Organon  Co.                               | 68622V106 | 06/10/2025     | Approve, on a non-binding advisory basis, the compensation of Organon's Named Executive Officers.                                                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |  10422           |                0 | FOR         | 10422.000000                             | FOR                         |  |
| Alector, Inc.                              | 014442107 | 06/11/2025     | Advisory vote on executive compensation.                                                                                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES | 242548           |                0 | FOR         | 242548.000000                            | FOR                         |  |
| Aquestive Therapeutics, Inc.               | 03843E104 | 06/11/2025     | To approve, on a non-binding advisory basis, the compensation of our named executive officers.                                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |   3500           |                0 | AGAINST     | 3500.000000                              | AGAINST                     |  |
| Astria Therapeutics, Inc.                  | 04635X102 | 06/11/2025     | The approval, by non-binding advisory vote, of our executive compensation.                                                                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES | 711688           |                0 | AGAINST     | 711688.000000                            | AGAINST                     |  |
| Coherus BioSciences, Inc.                  | 19249H103 | 06/11/2025     | To vote on a non-binding, advisory basis to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote).                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |  10366           |                0 | AGAINST     | 10366.000000                             | AGAINST                     |  |
| Crinetics Pharmaceuticals, Inc.            | 22663K107 | 06/11/2025     | To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission;                                               | SECTION 14A SAY-ON-PAY VOTES |  47042           |                0 | FOR         | 47042.000000                             | FOR                         |  |
| CytomX Therapeutics, Inc.                  | 23284F105 | 06/11/2025     | To approve, on a nonbinding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders; and                                                                             | SECTION 14A SAY-ON-PAY VOTES |     36           |                0 | FOR         | 36.000000                                | FOR                         |  |
| Disc Medicine, Inc.                        | 254604101 | 06/11/2025     | To approve, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers.                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |    323           |                0 | FOR         | 323.000000                               | FOR                         |  |
| Disc Medicine, Inc.                        | 254604101 | 06/11/2025     | To recommend, by a non-binding advisory vote, the frequency of future advisory votes on the compensation paid to the Company's named executive officers.                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |    323           |                0 | ONE YEAR    | 323.000000                               | FOR                         |  |
| Dynavax Technologies Corporation           | 268158201 | 06/11/2025     | To approve, on an advisory basis, executive compensation for certain of our executive officers.                                                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES | 170000           |                0 | FOR         | 170000.000000                            | FOR                         |  |
| Dynavax Technologies Corporation           | 268158201 | 06/11/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |      0           |                0 |  |  |  |  |
| Intellia Therapeutics, Inc.                | 45826J105 | 06/11/2025     | Approval, on a non-binding advisory basis, of the compensation of our named executive officers ("NEOS").                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |    800           |                0 | AGAINST     | 800.000000                               | AGAINST                     |  |
| Intellia Therapeutics, Inc.                | 45826J105 | 06/11/2025     | A non-binding advisory vote on the frequency of future non-binding advisory votes on the compensation of our NEOS.                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |    800           |                0 | ONE YEAR    | 800.000000                               | FOR                         |  |
| Janux Therapeutics, Inc.                   | 47103J105 | 06/11/2025     | Approval, on an advisory basis, of the compensation of our named executive officers ("Say-On-Pay"), as disclosed in the accompanying Proxy Statement.                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES | 132470           |                0 | FOR         | 132470.000000                            | FOR                         |  |
| Janux Therapeutics, Inc.                   | 47103J105 | 06/11/2025     | Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compensation of our named executive officers.                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES | 132470           |                0 | ONE YEAR    | 132470.000000                            | FOR                         |  |
| Korro Bio, Inc.                            | 500946108 | 06/11/2025     | Non-Binding Advisory Vote to Approve the Compensation of our Named Executive Officers;                                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |  34824           |                0 | FOR         | 34824.000000                             | FOR                         |  |
| Korro Bio, Inc.                            | 500946108 | 06/11/2025     | Non-Binding Advisory Vote on the Frequency of Future Non-Binding Advisory Votes to Approve the Compensation of our Named Executive Officers                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |  34824           |                0 | ONE YEAR    | 34824.000000                             | FOR                         |  |
| Protara Therapeutics, Inc.                 | 74365U107 | 06/11/2025     | Approval, on an advisory basis, of the compensation of Protara Therapeutics, Inc.'s named executive officers, as disclosed in the proxy statement                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES | 122690           |                0 | FOR         | 122690.000000                            | FOR                         |  |
| Sage Therapeutics, Inc.                    | 78667J108 | 06/11/2025     | To hold a non-binding advisory vote to approve the compensation paid to our named executive officers.                                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES | 528423           |                0 | FOR         | 528423.000000                            | FOR                         |  |
| Tenax Therapeutics, Inc.                   | 88032L605 | 06/11/2025     | Approval, on an advisory basis, of Tenax Therapeutics, Inc.'s 2024 named executive officer compensation.                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES | 167114           |                0 | FOR         | 167114.000000                            | FOR                         |  |
| Tenax Therapeutics, Inc.                   | 88032L605 | 06/11/2025     | Approval, on an advisory basis, on the frequency of future advisory votes on named executive officer compensation.                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES | 167114           |                0 | ONE YEAR    | 167114.000000                            | AGAINST                     |  |
| BioCryst Pharmaceuticals, Inc.             | 09058V103 | 06/12/2025     | To hold a non-binding, advisory vote regarding executive compensation.                                                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |   3000           |                0 | FOR         | 3000.000000                              | FOR                         |  |
| Exact Sciences Corporation                 | 30063P105 | 06/12/2025     | To approve, on an advisory basis, the compensation of our named executive officers.                                                                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |   4997           |                0 | FOR         | 4997.000000                              | FOR                         |  |
| Natera, Inc.                               | 632307104 | 06/12/2025     | To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.'s named executive officers as disclosed in the proxy statement.                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |   5000           |                0 | FOR         | 5000.000000                              | FOR                         |  |
| Neurogene, Inc.                            | 64135M105 | 06/12/2025     | To approve on an an (non-binding) basis the compensation of the Company's named executive officers.                                                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |  25736           |                0 | FOR         | 25736.000000                             | FOR                         |  |
| Solid Biosciences Inc.                     | 83422E204 | 06/12/2025     | The approval of an advisory vote on executive compensation.                                                                                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |  33035           |                0 | AGAINST     | 33035.000000                             | AGAINST                     |  |
| Spero Therapeutics, Inc.                   | 84833T103 | 06/12/2025     | To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement.                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES | 801277           |                0 | FOR         | 801277.000000                            | FOR                         |  |
| Vaxcyte, Inc.                              | 92243G108 | 06/12/2025     | Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.                                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |  15642           |                0 | AGAINST     | 15642.000000                             | AGAINST                     |  |
| Xencor, Inc.                               | 98401F105 | 06/12/2025     | To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers, as disclosed in the accompanying Proxy Statement;                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES | 344526           |                0 | FOR         | 344526.000000                            | FOR                         |  |
| Cellectar Biosciences, Inc.                | 15117F880 | 06/13/2025     | To hold a non-binding advisory vote to approve named executive officer compensation; and                                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |  40228           |                0 | FOR         | 40228.000000                             | FOR                         |  |
| Regeneron Pharmaceuticals, Inc.            | 75886F107 | 06/13/2025     | Proposal to approve, on an advisory basis, executive compensation.                                                                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |   1287           |                0 | FOR         | 1287.000000                              | FOR                         |  |
| 4D Molecular Therapeutics, Inc.            | 35104E100 | 06/17/2025     | Approval, on an advisory, non-binding basis, of the compensation of the Company's named executive officers ("say-on-pay vote").                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |   6000           |                0 | FOR         | 6000.000000                              | FOR                         |  |
| 4D Molecular Therapeutics, Inc.            | 35104E100 | 06/17/2025     | Approval, on an advisory, non-binding basis, of the frequency of future advisory say-on-pay votes.                                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |   6000           |                0 | ONE YEAR    | 6000.000000                              | FOR                         |  |
| AnaptysBio, Inc.                           | 032724106 | 06/17/2025     | To conduct a non-binding advisory vote on the compensation of our named executive officers as disclosed in the accompanying materials.                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |   3398           |                0 | AGAINST     | 3398.000000                              | AGAINST                     |  |
| AnaptysBio, Inc.                           | 032724106 | 06/17/2025     | Non-binding advisory vote on the frequency of holding future advisory votes regarding named executive officer compensation.                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |   3398           |                0 | ONE YEAR    | 3398.000000                              | FOR                         |  |
| Apogee Therapeutics, Inc.                  | 03770N101 | 06/17/2025     | Vote on the frequency of future advisory votes to approve our named executive officers compensation.                                                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |  86588           |                0 | ONE YEAR    | 86588.000000                             | FOR                         |  |
| Avalo Therapeutics, Inc.                   | 05338F306 | 06/17/2025     | To approve, on a nonbinding advisory basis, a "Say-on-Pay" resolution regarding the compensation of our named executive officers;                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |  10000           |                0 | FOR         | 10000.000000                             | FOR                         |  |
| Biogen Inc.                                | 09062X103 | 06/17/2025     | Say on Pay - To hold an advisory vote on executive compensation.                                                                                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |   1500           |                0 | AGAINST     | 1500.000000                              | AGAINST                     |  |
| Kezar Life Sciences, Inc.                  | 49372L209 | 06/17/2025     | Advisory vote on the compensation paid to our named executive officers.                                                                                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES | 107589           |                0 | AGAINST     | 107589.000000                            | AGAINST                     |  |
| Liquidia Corporation                       | 53635D202 | 06/17/2025     | To approve, on an advisory basis, the compensation of our named executive officers.                                                                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |    285           |                0 | FOR         | 285.000000                               | FOR                         |  |
| Monopar Therapeutics Inc.                  | 61023L207 | 06/17/2025     | To approve the compensation of our named executive officers on an advisory, non-binding basis.                                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES | 100224           |                0 | FOR         | 100224.000000                            | FOR                         |  |
| Monopar Therapeutics Inc.                  | 61023L207 | 06/17/2025     | To approve the frequency of future advisory votes on the compensation of our named executive officers on an advisory, non-binding basis                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES | 100224           |                0 | ONE YEAR    | 100224.000000                            | FOR                         |  |
| PTC Therapeutics, Inc.                     | 69366J200 | 06/17/2025     | Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement.                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |  44896           |                0 | FOR         | 44896.000000                             | FOR                         |  |
| Zentalis Pharmaceuticals, Inc.             | 98943L107 | 06/17/2025     | To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.                                                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |  40811           |                0 | AGAINST     | 40811.000000                             | AGAINST                     |  |
| Agios Pharmaceuticals, Inc.                | 00847X104 | 06/18/2025     | To vote, on an advisory basis, to approve the compensation paid to our named executive officers.                                                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |  27181           |                0 | FOR         | 27181.000000                             | FOR                         |  |
| Ardelyx, Inc.                              | 039697107 | 06/18/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in the proxy statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay");                    | SECTION 14A SAY-ON-PAY VOTES | 357889           |                0 | FOR         | 357889.000000                            | FOR                         |  |
| Cidara Therapeutics, Inc.                  | 171757206 | 06/18/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in: the proxy statement.                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |  18938           |                0 | AGAINST     | 18938.000000                             | AGAINST                     |  |
| EyePoint Pharmaceuticals, Inc.             | 30233G209 | 06/18/2025     | To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement.                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |    114           |                0 | FOR         | 114.000000                               | FOR                         |  |
| EyePoint Pharmaceuticals, Inc.             | 30233G209 | 06/18/2025     | To vote, on an advisory basis, on the frequency of advisory stockholder votes on the compensation paid to our named executive officers.                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |    114           |                0 | ONE YEAR    | 114.000000                               | FOR                         |  |
| Leap Therapeutics, Inc.                    | 52187K200 | 06/18/2025     | Advisory vote on executive compensation paid to named executive officers ("Say-on-Pay Proposal").                                                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES | 100000           |                0 | FOR         | 100000.000000                            | FOR                         |  |
| Nuvalent, Inc.                             | 670703107 | 06/18/2025     | To approve, on an advisory basis, the compensation paid to our named executive officers.                                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |   2854           |                0 | AGAINST     | 2854.000000                              | AGAINST                     |  |
| Recursion Pharmaceuticals, Inc.            | 75629V104 | 06/18/2025     | Advisory vote to approve executive compensation as disclosed in the 2025 Proxy Statement.                                                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |  35000           |                0 | FOR         | 35000.000000                             | FOR                         |  |
| Rocket Pharmaceuticals, Inc.               | 77313F106 | 06/18/2025     | Consider and act upon a non-binding, advisory vote on the compensation of our named executive officers;                                                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES | 159452           |                0 | FOR         | 159452.000000                            | FOR                         |  |
| Zai Lab Limited                            | 98887Q104 | 06/18/2025     | THAT, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement, is hereby approved.                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES | 481594           |                0 | AGAINST     | 481594.000000                            | AGAINST                     |  |
| BridgeBio Pharma, Inc.                     | 10806X102 | 06/20/2025     | To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.                                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES | 296932           |                0 | AGAINST     | 296932.000000                            | AGAINST                     |  |
| NextCure, Inc.                             | 65343E207 | 06/20/2025     | Approval, on an advisory basis, of the compensation paid by Company to its named executive officers.                                                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES | 119955           |                0 | FOR         | 119955.000000                            | FOR                         |  |
| NextCure, Inc.                             | 65343E207 | 06/20/2025     | Approval, on an advisory basis, of whether a vote on the compensation of our named executive officers should take place every one year, every two years or every three years.                                                                                                          | SECTION 14A SAY-ON-PAY VOTES | 119955           |                0 | ONE YEAR    | 119955.000000                            | FOR                         |  |
| Protagonist Therapeutics, Inc.             | 74366E102 | 06/20/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES | 843380           |                0 | FOR         | 843380.000000                            | FOR                         |  |
| Viridian Therapeutics, Inc.                | 92790C104 | 06/20/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES | 112768           |                0 | AGAINST     | 112768.000000                            | AGAINST                     |  |
| Structure Therapeutics Inc.                | 86366E106 | 06/23/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |  20319           |                0 | FOR         | 20319.000000                             | FOR                         |  |
| Structure Therapeutics Inc.                | 86366E106 | 06/23/2025     | To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers.                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |  20319           |                0 | ONE YEAR    | 20319.000000                             | FOR                         |  |
| Rhythm Pharmaceuticals, Inc.               | 76243J105 | 06/24/2025     | Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.                                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |  13716           |                0 | AGAINST     | 13716.000000                             | AGAINST                     |  |
| Arvinas, Inc.                              | 04335A105 | 06/25/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES | 111797           |                0 | FOR         | 111797.000000                            | FOR                         |  |
| Gossamer Bio, Inc.                         | 38341P102 | 06/25/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement.                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES | 227228           |                0 | FOR         | 227228.000000                            | FOR                         |  |
| Kymera Therapeutics, Inc.                  | 501575104 | 06/25/2025     | To approve, on a non-binding advisory basis, the compensation of our named executive officers; and                                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |   8886           |                0 | FOR         | 8886.000000                              | FOR                         |  |
| Fulcrum Therapeutics, Inc.                 | 359616109 | 06/26/2025     | A non-binding advisory vote on executive compensation;                                                                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES | 447673           |                0 | FOR         | 447673.000000                            | FOR                         |  |
| Fulcrum Therapeutics, Inc.                 | 359616109 | 06/26/2025     | A non-binding advisory vote on the frequency of future executive compensation advisory votes; and                                                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES | 447673           |                0 | ONE YEAR    | 447673.000000                            | FOR                         |  |
| Revolution Medicines, Inc.                 | 76155X100 | 06/26/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").                                   | SECTION 14A SAY-ON-PAY VOTES | 159374           |                0 | FOR         | 159374.000000                            | FOR                         |  |
| Springworks Therapeutics, Inc.             | 85205L107 | 06/26/2025     | A proposal to approve, on a non-binding, advisory basis, certain compensation that may be paid or become payable to the Company's named executive officers in connection with the Merger.                                                                                              | SECTION 14A SAY-ON-PAY VOTES |  24072           |                0 | FOR         | 24072.000000                             | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** ADAR1 Capital Management, LLC

**By (Signature):** Stephen Scipione

**By (Printed Signature):** Stephen Scipione

**By (Title):** Chief Compliance Officer

**Date:** 08/27/2025